User login
Key clinical point: Pediatric patients with irritable bowel syndrome (IBS) and normal weight had higher levels of fecal calprotectin than those with IBS and obesity, suggesting the role of obesity and intestinal inflammation in the development and manifestations of IBS in children.
Major finding: The mean calprotectin levels were significantly higher in patients with body mass index <85th vs 85th to <95th percentile (P = .028) and ≥95th percentile (P ≥ .025), with the difference being prominent among children aged between 6 and 12 years (P = .029) but not among adolescents aged between 12 and 18 years (P = .139).
Study details: The data come from a retrospective analysis of 277 pediatric patients with IBS.
Disclosures: This study did not receive any funding. The authors declared no conflicts of interest.
Source: Kim JH et al. Association between body mass index and fecal calprotectin levels in children and adolescents with irritable bowel syndrome. Medicine (Baltimore). 2022;101(32):e29968 (Aug 12). Doi: 10.1097/MD.0000000000029968.
Key clinical point: Pediatric patients with irritable bowel syndrome (IBS) and normal weight had higher levels of fecal calprotectin than those with IBS and obesity, suggesting the role of obesity and intestinal inflammation in the development and manifestations of IBS in children.
Major finding: The mean calprotectin levels were significantly higher in patients with body mass index <85th vs 85th to <95th percentile (P = .028) and ≥95th percentile (P ≥ .025), with the difference being prominent among children aged between 6 and 12 years (P = .029) but not among adolescents aged between 12 and 18 years (P = .139).
Study details: The data come from a retrospective analysis of 277 pediatric patients with IBS.
Disclosures: This study did not receive any funding. The authors declared no conflicts of interest.
Source: Kim JH et al. Association between body mass index and fecal calprotectin levels in children and adolescents with irritable bowel syndrome. Medicine (Baltimore). 2022;101(32):e29968 (Aug 12). Doi: 10.1097/MD.0000000000029968.
Key clinical point: Pediatric patients with irritable bowel syndrome (IBS) and normal weight had higher levels of fecal calprotectin than those with IBS and obesity, suggesting the role of obesity and intestinal inflammation in the development and manifestations of IBS in children.
Major finding: The mean calprotectin levels were significantly higher in patients with body mass index <85th vs 85th to <95th percentile (P = .028) and ≥95th percentile (P ≥ .025), with the difference being prominent among children aged between 6 and 12 years (P = .029) but not among adolescents aged between 12 and 18 years (P = .139).
Study details: The data come from a retrospective analysis of 277 pediatric patients with IBS.
Disclosures: This study did not receive any funding. The authors declared no conflicts of interest.
Source: Kim JH et al. Association between body mass index and fecal calprotectin levels in children and adolescents with irritable bowel syndrome. Medicine (Baltimore). 2022;101(32):e29968 (Aug 12). Doi: 10.1097/MD.0000000000029968.